In lobular BC, the loss of E-cadherin expression that occurs early in the tumorigenic process [46], could be rescue by ROS1 synthetic lethality, an effect clinically actionable using ROS1 inhibitors [47]. The gene discussed is ROS1; the disease is breast cancer.